1. Hauser WA,Annegers JF,Rocca WA (1996). Descriptive epidemiology of epilepsy: contributions of population-based studies from Rochester, Minnesota. Mayo Clin Proc, 71, 576-86.
2. Armin Haerer,Dallas Anderson,Bruce Schoenberg (1986). Prevalence and clinical features of epilepsy in a biracial United States population Epilepsia. Epilepsia, 27(1), 66-75.
3. Hauser WA,Annegers JF,Rocca WA (1996). Descriptive epidemiology of epilepsy: contributions of population-based studies from Rochester, Minnesota. Mayo Clin Proc, 71, 578-86.
4. Hauser WA,Annegers JF,Kurland LT (1991). The prevalence of epilepsy in Rochester, Minnesota: 1940-1980 Epilepsia. Epilepsia, 32, 429-445.
5. Hauser WA,Annegers JF,Kurland LT (1993). Incidence of epilepsy and unprovoked seizures in Rochester, Minnesota: 1935-1984 Epilepsia. Epilepsia, 34, 453-468.
6. John Annegers,Walter Rocca,W. Hauser (1996). Causes of epilepsy: contributions of the Rochester epidemiology project Mayo Clin Proc. Mayo Clinic Proceedings, 71(6), 570-575.
7. Giller Nohria V,Ganaxolone (2004). Ganaxolone. Neurotherapeutics, 4, 102-105.
8. Carter R.B,Wood P.L,Wieland S,Hawkinson J.E,Belelli D,Lambert J.J,White H.S,Wolf H.H,Mirsadeghi S,Tahir S.H,Bolger M.B,Lan N.C,Gee K.W (1997). Characterization of the anticonvulsant properties of ganaxolone (CCD 1042; 3(-hydroxy-3(- methyl-5(-pregnan-20-one), a selective, high-affinity, steroid modulator of the gamma-aminobutyric acidA receptor. J. Pharmacol. Exp. Ther, 280, 1284 1295.
9. M. Le´skiewicz,B. Budziszewska,L. Jaworska-Feil,M. Kubera,W. Basta-Kaim Lason (2003). Le´skiewicz M, Budziszewska B, Jaworska-Feil L, Kubera M, Basta-Kaim Lason W, Inhibitory effect of some neuroactive steroids on cocaine-induced kindling in mice. Polish J. Pharmacol, 55, 1131-1136.
10. M. Rogawski,D. Reddy (2004). Neurosteroids: endogenous modulators of seizure susceptibility In: Rho, J.M., Sankar, R., Cavazos, J (Eds.), Epilepsy: Scientific Foundations of Clinical Practice. Marcel Dekker, 319-355.
11. Baldelli Biagini G,Pradelli Longo D,Zini I,Avoli Rogawski M.A (2006). Endogenous neurosteroids modulate epileptogenesis in a model of temporal lobe epilepsy. Exp. Neurol, 201, 519-524.
12. A. Freitas (1999). Anticonvulsant and Sodium Channel-Blocking Properties of Novel 10,11-Dihydro-5H-dibenz[b,f]azepine-5-carboxamide Derivatives. P, Learmonth D.A, Cunha R.A, Garrett J, Soares-da-Silva P, Anticonvulsant and sodium channel-blocking properties of novel 10,11-dihydro- 5H-dibenz [b,f] azepine-5-carboxamide derivatives. J. Med. Chem, 42, 2582-2587.
13. Ambrosio,Silva Araujo,I.,Malva Soaresda- Silva,P. Carvalho,A. Carvalho,C. (2000). Neurotoxic/ neuroprotective profile of carbamazepine, oxcarba-zepine and two new putative antiepileptic drugs, BIA 2-093 and BIA 2- 024. Eur. J. Pharmacol, 406, 191-201.
14. Cunha R.A,Coelho J.E,Costenla A.R,Parada Lopes L.V,de A,Sebastiao A.M,Ribeiro J.A,Effects carbamazepine (2002). Effects of carbamazepine and novel 10,11- dihydro-5H dibenz[b,f]azepine- 5-carboxamide derivatives on synaptic transmission in rat hippocampal slices. Pharmacol. Toxicol, 90, 208-213.
15. Soares-da-Silva Almeida L (2007). Eslicarbazepine Acetate (BIA 2-093). Neurotherapeutics, 4, 88-96.
16. Ward J,Caprio V (2006). A radical mediated approach to the core structure of Huperzine A. Tetrahedron Lett, 47, 553-556.
17. Bialer M,Johannessen S.I,Kupferberg H.J,Perucca Levy R.H,Tomson T (2004). Progress report on new antiepileptic drugs: a summary of the Seventh Eilat Conference (EILAT VII).
18. Wallis Panizzon,K. Niquet,J. Masaratis,L. Baldwin,R. Wasterlain,C. (2000). Wallis R.A, Panizzon K.L, Niquet J, Masaratis L, Baldwin R, Wasterlain C.G, Neuroprotective effects of the anticonvulsant, fluorofelbamate. Epilepsia, 41(7), 162.
19. H. White,S. Schachter,D. Lee,J. Xiaoshen,D. Eisenberg (2005). White H.S, Schachter S, Lee D, Xiaoshen J, Eisenberg D, Anticonvulsant activity of Huperzine A, an alkaloid extract of Chinese club moss (Huperzia serrata). Epilepsia, 46(8), 220.
20. A. Zangara (2003). The psychopharmacology of huperzine A: an alkaloid with cognitive enhancing and neuroprotective properties of interest in the treatment of Alzheimer’s disease. Pharmacol. Biochem. Behav, 75, 675-686.
21. H. White,A. Srivastava,B. Klein (2006). White H, Srivastava A, Klein B et al, The novel investigational neuromodulator RWJ-333369 displays a broad-spectrum anticonvulsant profile in rodent seizure and epilepsy models (abstract). Epilepsia
22. Grabenstatter H.L,Dudek F.E,A. AED,carisbamate (2008). A new potential AED, carisbamate, substantially reduces spontaneous motor seizures in rats with kainate‐induced epilepsy. Epilepsia, 49, 1787-1794.
23. Niespodziany I,Leclere N,Matagne A,Wolff C (2009). Brivaracetam modulates Na+ currents expressed in a neuroblastoma cell line compared with carbamazepine. Epilepsia, 50, 107.
24. Matagne Kaminski R.M,Gillard Leclercq K,Kenda Michel P,Klitgaard Talaga P,generalized epilepsy (2008). SV2A protein is a broad-spectrum anticonvulsant target: Functional correlation between protein binding and seizure protection in models of both partial and generalized epilepsy. Neuropharmacology, 54, 715-720.
25. Matagne A,Kenda Margineanu D.G,Klitgaard Michel P,Anti-convulsive (2008). Anti‐convulsive and anti‐epileptic properties of brivaracetam (ucb 34714), a high‐affinity ligand for the synaptic vesicle protein, SV2A. 2008a, 154, 1662-1671.
26. Johnston Berwick J,Martindale Jones M,Kennerly Martin C,Redgrave P,Mayhew J.E (2008). Fine detail of neurovascular coupling revealed by spatio-temporal analysis of the hemodynamic response to single whisker stimulation in rat barrel cortex. J. Neurophysiol, 99, 787-798.
27. Netzer Rundfeldt C (2000). The novel anticonvulsant retigabine activates M-currents in Chinese hamster ovary-cells transfected with human KCNQ2/3 subunits. Neurosci. Lett, 282, 73-76.
28. Yagen Spiegelstein O,Bialer M (1999). Epile-psia.1999. Epilepsia, 40, 545-552.
29. M. Bialer,S. Johannessen,H. Kupferberg,R. Levy,P. Loiseau,E. Perucca (2001). Progress report on new antiepileptic drugs: a summary of the Fifth Eilat Conference (EILAT V).
30. M. Bialer,S. Johannessen,H. Kupferberg,R. Levy,P. Loiseau,E. Perucca (2002). Progress report on new antiepileptic drugs: a summary of the Sixth Eilat Conference (EILAT VI).
31. Bialer M,Johannessen S.I,Kupferberg H.J,Perucca Levy R.H,Tomson T (2004). Progress report on new antiepileptic drugs: a summary of the Seventh Eilat Conference (EILAT VII).
32. Bingham Parsons A.A,Read Raval P,Upton Thompson M (2001). Tonabersat (SB-220453) a novel benzopyran with anticonvulsant properties attenuates trigeminal nerve induced neurovascular reflexes. Br. J. Pharmacol, 132, 1549-1557.
33. Bialer M,Johannessen S.I,Kupferberg H.J,Perucca Levy R.H,Tomson T (2010). Progress report on new antiepileptic drugs: A summary of the Tenth Eilat Conference (EILAT X).
34. Bialer M,Clinical valpromide (1991). Clinical pharmacology of valpromide. Clin. Pharmacokinet, 20, 114-122.
35. Johannessen Bialer M,Kupferberg H.J,Perucca Levy R.H,Tomson T (2007). Progress report on new antiepileptic drugs: A summary of the Eigth Eilat Conference (EILAT VIII).
36. A. Funk,R. Ricci,Anderson,Arana De Colle,C.,Wang,George (2008). Single doses of JZP- 4 decrease cortical excitability. A transcranial magnetic stimulation study. American Epilepsy Society 2008 Annual Meeting
37. Binnie C.D,Kasteleijn-Nolst D.G.A,De R.A (1986). Photosensitivity as a model for acute antiepileptic drug studies. Electroencephalogr. Clin. Neurophysiol, 63, 35-41.
38. H. White,Erika Scholl,Brian Klein,Sean Flynn,Timothy Pruess,Brad Green,Liuyin Zhang,Grzegorz Bulaj (2009). Developing novel antiepileptic drugs: characterization of NAX 5055, a systemically active galanin analog, in epilepsy models Neurotherapeutics. Neurotherapeutics, 6(2), 372-380.
39. Y. Hashizume,T. Hanada,A. Ogasawara,M. Ueno,Y. Nishizawa (2008). Anticonvulsant activity of perampanel, a selective AMPA receptor antagonist, in rodent models of epileptic seizure. Poster P02.113 presented at the 60th Annual Meeting of the American Academy of Neurology
40. G. Shaltiel,M. Shirley,Ora Belmaker,R. Agam,G. (2007). Effect of valproate derivatives on human brain myo-inositol-1-phosphate (MIP) synthase activity and amphetamine-induced rearing. Pharmacol. Report, 59, 402-407.
